Reports Q1 revenue $4.06M, consensus $1.92M. “The data presented on our ctLNP and iqDNA platforms highlight their maturity and differentiation as the foundation for building programs in hematology,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “Our unique non-viral delivery and cargo may unlock a series of non-viral in vivo therapeutic candidates, starting with sickle cell disease and hemophilia A. We believe our medicines could have a drug-like, redosable in vivo profile, meaning they can surpass what is possible for current viral, biologic and ex vivo approaches to reach people on a global scale.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GBIO:
- Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Generation Bio presents preclinical data on iqDNA, ctLNP platforms
- Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- Third Harmonic Bio appoints McDonough to board of directors